ClinicalTrials.gg

Program

socazolimab

Also written as “ZKAB001 5mg/kg”, “ZKAB001 10mg/kg” and “ZKAB001 15mg/kg”.

Its studies are mostly in Uterine Cervical Neoplasms · Osteosarcoma · Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Melanoma, led by 2 companies.

Furthest: phase 3, since Apr 21, 20209 company-led studies, 2 open or runningNext primary completion: Sep 1, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lee's Pharmaceutical81 open or runningphase 3since Apr 21, 2020Sep 12, 2018Sep 1, 2027phase 3 · NCT06459687
Suzhou BlueHorse Therapeutics11 open or runningphase 2since Feb 26, 2026Feb 26, 2026Dec 31, 2027phase 2 · NCT07444437

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 12, 2018First study: phase 1 study in Uterine Cervical NeoplasmsNew to Lee's PharmaceuticalLee's Pharmaceutical · NCT03676959 · 101 enrolled · China
  2. Sep 13, 20182 phase 2 studiesLee's Pharmaceutical · NCT03676985, NCT03676946
  3. Apr 21, 2020Phase 3 study in High-grade OsteosarcomaLee's Pharmaceutical · NCT04359550 · 362 enrolled
  4. Oct 22, 2020Phase 1 study in Biliary Tract NeoplasmsLee's Pharmaceutical · NCT04608786 · 10 enrolled · China
  5. Apr 14, 2021Phase 2 study in Local Progression or Metastatic Melanoma With Failed First-line TreatmentLee's Pharmaceutical · NCT04849260 · 54 enrolled · China
  6. Apr 29, 2021Phase 3 study in Small Cell Lung CarcinomaLee's Pharmaceutical · NCT04878016 · 498 enrolled · China
  7. Jun 3, 2024Phase 3 study in Uterine Cervical NeoplasmsLee's Pharmaceutical · NCT06459687 · 440 planned · China
  8. Feb 26, 2026Suzhou BlueHorse Therapeutics's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Suzhou BlueHorse TherapeuticsSuzhou BlueHorse Therapeutics · NCT07444437 · 45 planned · China

Ahead

  1. Sep 1, 2027Primary completion: phase 3 study in Uterine Cervical NeoplasmsLee's Pharmaceutical · NCT06459687
  2. Dec 31, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungSuzhou BlueHorse Therapeutics · NCT07444437

TargetBeta

CD274 →read by rule
“A human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), ”NCIt, by rule
“Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule

Other programs on CD274

ProgramCompanyFurthest phaseStudies
durvalumabruleAstraZenecaphase 4102
adebrelimabruleJiangsu HengRui Medicinephase 351
pumitamigBioNTechphase 334
benmelstobartruleSino Biopharmaceuticalphase 333
retlirafusp alfaruleJiangsu HengRui Medicinephase 320
Anti-PD-L1 Antibody-drug Conjugate HLX43Fosun Pharmaphase 317
erfonrilimabruleAlphamab Oncologyphase 314
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rulenanjing-leads-biolabs-co-ltdphase 310
acasunlimabruleGenmabphase 36
sotiburafusp alfarulehuabo-biopharm-co-ltdphase 35
fetrastobart vedotinPfizerphase 32
HLX37Fosun Pharmaphase 32

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07444437Carcinoma, Non-Small-Cell Lung · China2RecruitingSuzhou BlueHorse TherapeuticsDec 31, 202745
NCT06459687Uterine Cervical Neoplasms · China3RecruitingLee's PharmaceuticalSep 1, 2027440
NCT04878016Small Cell Lung Carcinoma · China3CompletedLee's PharmaceuticalOct 13, 2023498
NCT04849260Local Progression or Metastatic Melanoma With Failed First-line Treatment · China2UNKNOWNLee's PharmaceuticalMay 31, 202254
NCT04608786Biliary Tract Neoplasms · China1UNKNOWNLee's PharmaceuticalDec 1, 202210
NCT04359550High-grade Osteosarcoma3UNKNOWNLee's PharmaceuticalJun 1, 2022362
NCT03676985Osteosarcoma · China2UNKNOWNLee's PharmaceuticalFeb 14, 202015
NCT03676946Carcinoma, Transitional Cell · China2UNKNOWNLee's PharmaceuticalFeb 14, 202015
NCT03676959Uterine Cervical Neoplasms · China1UNKNOWNLee's PharmaceuticalMay 15, 2022101

How it is read

Names in the registry

  • “ZKAB001 5mg/kg”, 4 entries
  • “ZKAB001 10mg/kg”, 3 entries
  • “ZKAB001 15mg/kg”, 3 entries
  • “PD-1 / PD-L1 monoclonal antibody”, 1 entry
  • “Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.